EP0266993A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Method and therapeutic compositions for the treatment of bleeding disorders
Assignee: Genentech Inc
•
Filing: 1987-11-02
•
Granted: —
•
Expires: 2007-11-02
Abstract
Abstract The use of tissue factor protein or antagonists thereof in therapeutic compositions for the treatment of bleeding disorders, for example those characterized by a tendency toward hemorrhage or a hypercoagulative state.
Inventors
- 👤 Donogh Paul O'brien
- 👤 Gordon Allen Vehar
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 21:58
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/745; A; A61; A61P; A61P7/00; A61P7/04; A61K; A61K38/00
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
6 words
Tissue factor protein for pharmaceutical use.
Claim 2
Dependent Claim
6 words
Tissue factor protein for pharmaceutical use.
Claim 3
Dependent Claim
24 words
The use of tissue factor protein in the preparation of a medicament for treating bleeding disorders which are characterised by a tendency to hemorrhage.
Claim 4
Dependent Claim
24 words
The use of tissue factor protein in the preparation of a medicament for treating bleeding disorders which are characterised by a tendency to hemorrhage.
Claim 5
Dependent Claim
19 words
The use according to claim 2 wherein the bleeding disorder is associated with a deficiency of a coagulation factor.
Claim 6
Dependent Claim
17 words
The use according to claim 3 wherein the deficient coagulation factor is a deficiency of factor VIII.
Claim 7
Dependent Claim
17 words
The use according to claim 3 wherein the deficient coagulation factor is a deficiency of factor IX.
Claim 8
Dependent Claim
17 words
The use according to claim 3 wherein the deficient coagulation factor is a deficiency of factor XIII.
Claim 9
Dependent Claim
17 words
The use according to claim 3 wherein the deficient coagulation factor is a deficiency of factor XI.
Claim 10
Dependent Claim
15 words
The use according to claim 2 wherein the bleeding disorder is an acquired coagulation disorder.
Claim 11
Dependent Claim
19 words
The use according to any one of claims 2 to 8 wherein the medicament is prepared for intravenous administration.
Claim 12
Dependent Claim
19 words
The use according to any one of claims 2 to 8 wherein the medicament is prepared for oral administration.
Claim 13
Dependent Claim
30 words
The use according to any one of claims 2 to 10 wherein the medicament comprises a therapeutically effective dose in the range of about from 50 U/kg to 250 U/kg.
Claim 14
Dependent Claim
23 words
The use according to claim 11 wherein the therapeutically effective dose is in the range of about from 75 U/kg to 200 U/kg.
Claim 15
Dependent Claim
7 words
Tissue factor protein antagonist for pharmaceutical use.
Claim 16
Dependent Claim
7 words
Tissue factor protein antagonist for pharmaceutical use.
Claim 17
Dependent Claim
21 words
Use of tissue factor protein antagonist in the preparation of a medicament for treating an animal with a hypercoagulative bleeding disorder.
Claim 18
Dependent Claim
21 words
Use of tissue factor protein antagonist in the preparation of a medicament for treating an animal with a hypercoagulative bleeding disorder.
Claim 19
Dependent Claim
28 words
A therapeutic dosage form for administration to an animal with a bleeding disorder characterized by a tendency to hemorrhage comprising tissue factor protein and a pharmaceutically acceptable vehicle.
Claim 20
Dependent Claim
28 words
A therapeutic dosage form for administration to an animal with a bleeding disorder characterized by a tendency to hemorrhage comprising tissue factor protein and a pharmaceutically acceptable vehicle.
Claim 21
Dependent Claim
9 words
The dosage form of claim 15 which is sterile.
Claim 22
Dependent Claim
11 words
The dosage form of claim 15 which is isotonic to blood.
Claim 23
Dependent Claim
15 words
The dosage form of claim 15 wherein the vehicle is a liphophilic sustained release formulation.
Claim 24
Dependent Claim
29 words
A therapeutic dosage form for administration to an animal with a bleeding disorder characterized by a hypercoagulative state comprising a tissue factor protein antagonist and a pharmaceutically acceptable vehicle.
Claim 25
Dependent Claim
29 words
A therapeutic dosage form for administration to an animal with a bleeding disorder characterized by a hypercoagulative state comprising a tissue factor protein antagonist and a pharmaceutically acceptable vehicle.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.